Valeant Pharmaceuticals reported $713M in EBITDA for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Amgen AMGN:US USD 3.04B 460M
Ani Pharmaceuticals ANIP:US USD 11.9M 7.95M
Aurora Cannabis Inc ACB:CN CAD -63067000 2.66M
Biogen BIIB:US USD 992.8M 82.9M
Bristol Myers Squibb BMY:US USD 4.66B 663M
Canopy Growth Corp WEED:CN CAD -95980000 11.78M
Catalent CTLT:US USD 161M 200M
Corcept Therapeutics CORT:US USD 32.13M 581K
Danaher DHR:US USD 2.86B 306M
Drreddys Laboratories RDY:US INR 20.73B 1.45B
Endo International Ordinary Shares ENDP:US USD 151.76M 22.28M
Gilead Sciences GILD:US USD 2.7B 662M
Horizon Pharma HZNP:US USD 287.24M 42.81M
Nektar Therapeutics NKTR:US USD -34794000 9.48M
Pacira Pharmaceuticals PCRX:US USD 41.98M 7.94M
Perrigo Ordinary Shares PRGO:US USD 140.7M 54.6M
Prestige Brands PBH:US USD 95.31M 2.68M
Revance Therapeutics RVNC:US USD -72045000 19.65M
Valeant Pharmaceuticals VRX:CN USD 713M 80M
Vertex Pharmaceuticals VRTX:US USD 1.16B 6.8M
Zoetis ZTS:US USD 840M 14M